Insulin rectal - Oramed Pharmaceuticals

Drug Profile

Insulin rectal - Oramed Pharmaceuticals

Alternative Names: Insulin suppository; ORMD 0802

Latest Information Update: 10 Mar 2011

Price : $50

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 04 Feb 2009 Adverse events and pharmacokinetic data from a phase Ia trial in Type I diabetes mellitus released by Oramed Pharmaceuticals
  • 23 Oct 2008 Phase-I clinical trials in South Africa (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top